References
- Kaszak I, Ruszczak A, Kanafa S, Kacprzak K, Król M, Jurka P: Current biomarkers of canine mammary tumors. Acta Ve t Scand 2018, 60(1):66.
- Gherman LM, Chiroi P, Nuţu A, Bica C, Berindan-Neagoe I: Profiling canine mammary tumors: A potential model for studying human breast cancer. Vet J 2023, 303:106055.
- Gherman ML, Zanoaga O, Budisan L, Raduly L, Berindan-Neagoe I: Doxorubicin as a Potential Treatment Option in Canine Mammary Tumors. Vet Sci 2023, 10(11).
- Burrai GP, Gabrieli A, Moccia V, Zappulli V, Porcellato I, Brachelente C, Pirino S, Polinas M, Antuofermo E: A Statistical Analysis of Risk Factors and Biological Behavior in Canine Mammary Tumors: A Multicenter Study. Animals (Basel) 2020, 10(9).
- Tavasoly A, Golshahi H, Rezaie A, Farhadi M: Classification and grading of canine malignant mammary tumors. Vet Res Forum 2013, 4(1):25–30.
- Shafiee R, Javanbakht J, Atyabi N, Kheradmand P, Kheradmand D, Bahrami A, Daraei H, Khadivar F: Diagnosis, classification and grading of canine mammary tumours as a model to study human breast cancer: an Clinico-Cytohistopathological study with environmental factors influencing public health and medicine. Cancer Cell Int 2013, 13:79.
- Hughes K, Dobson JM: Prognostic histopathological and molecular markers in feline mammary neoplasia. The Veterinary Journal 2012, 194(1):19–26.
- Huang S, Wa Q, Pan J, Peng X, Ren D, Huang Y, Chen X, Tang Y: Downregulation of miR-141-3p promotes bone metastasis via activating NF-κB signaling in prostate cancer. J Exp Clin Cancer Res 2017, 36(1):173.
- Chiorean R, Braicu C, Berindan-Neagoe I: Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth? Breast 2013, 22(6):1026–1033.
- Zimta AA, Tigu AB, Muntean M, Cenariu D, Slaby O, Berindan-Neagoe I: Molecular Links between Central Obesity and Breast Cancer. Int J Mol Sci 2019, 20(21).
- Raduly L, Cojocneanu-Petric R, Sarpataki O, Chira S, Atanasov AG, Braicu C, Berindan-Neagoe I, Marcus I: Canis lupus familiaris as relevant animal model for breast cancer – A comparative oncology review. Animal Science Papers and Reports 2018, 36(2):119–148.
- Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144(5):646–674.
- Estaller A, Kessler M, Wehrend A, Hirschberger J, Neumann S: Utility of Serum Ki-67 as a Marker for Malignancy in Dogs. Animals (Basel) 2022, 12(10).
- Salaritabar A, Berindan-Neagoe I, Darvish B, Hadjiakhoondi F, Manayi A, Devi KP, Barreca D, Orhan IE, Süntar I, Farooqi AA et al: Targeting Hedgehog signaling pathway: Paving the road for cancer therapy. Pharmacol Res 2019, 141:466–480.
- Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000, 182(3):311–322.
- Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991, 138(4):867–873.
- Cuylen S, Blaukopf C, Politi AZ, Müller-Reichert T, Neumann B, Poser I, Ellenberg J, Hyman AA, Gerlich DW: Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. Nature 2016, 535(7611):308–312.
- Neumann S, Schuettler J, Frenz M, Kaup FJ, Gessler F: Investigation of serum Ki-67 as a biomarker in tumor-bearing dogs. Res Vet Sci 2017, 110:16–21.
- Strzalka W, Ziemienowicz A: Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation. Ann Bot 2011, 107(7):1127–1140.
- Juríková M, Danihel Ľ, Polák Š, Varga I: Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. Acta Histochem 2016, 118(5):544–552.
- Löhr CV, Teifke JP, Failing K, Weiss E: Characterization of the proliferation state in canine mammary tumors by the standardized AgNOR method with postfixation and immunohistologic detection of Ki-67 and PCNA. Vet Pathol 1997, 34(3):212–221.
- Peña LL, Nieto AI, Pérez-Alenza D, Cuesta P, Castaño M: Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. J Vet Diagn Invest 1998, 10(3):237–246.
- Carvalho MI, Pires I, Prada J, Lobo L, Queiroga FL: Ki-67 and PCNA Expression in Canine Mammary Tumors and Adjacent Nonneoplastic Mammary Glands: Prognostic Impact by a Multivariate Survival Analysis. Vet Pathol 2016, 53(6):1138–1146.
- Hussain S, Saxena S, Shrivastava S, Mohanty AK, Kumar S, Singh RJ, Kumar A, Wani SA, Gandham RK, Kumar N et al: Gene expression profiling of spontaneously occurring canine mammary tumours: Insight into gene networks and pathways linked to cancer pathogenesis. PLoS One 2018, 13(12):e0208656.
- Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, Yu M, Lin J, Cui Q: The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Int J Mol Sci 2020, 21(6).
- Alexander A, Karakas C, Chen X, Carey JP, Yi M, Bondy M, Thompson P, Cheung KL, Ellis IO, Gong Y et al: Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget 2017, 8(9):14897–14911.
- Sana M, Malik HJ: Current and emerging breast cancer biomarkers. J Cancer Res Ther 2015, 11(3):508–513.
- Piezzo M, Cocco S, Caputo R, Cianniello D, Gioia GD, Lauro VD, Fusco G, Martinelli C, Nuzzo F, Pensabene M et al: Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. Int J Mol Sci 2020, 21(18).
- Braicu C, Pileczki V, Irimie A, Berindan-Neagoe I: p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells. Mol Cell Biochem 2013, 381(1–2):61–68.
- Montalto FI, De Amicis F: Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma. Cells 2020, 9(12).
- Sfacteria A, Bertani C, Costantino G, Del Bue M, Paiardini M, Cervasi B, Piedimonte A, De Vico G: Cyclin D1 expression in pre-cancerous and cancerous lesions of the canine mammary gland. J Comp Pathol 2003, 128(4):245–251.
- Klopfleisch R, von Euler H, Sarli G, Pinho SS, Gärtner F, Gruber AD: Molecular carcinogenesis of canine mammary tumors: news from an old disease. Vet Pathol 2011, 48(1):98–116.
- Klopfleisch R, Gruber AD: Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands. Res Vet Sci 2009, 87(1):91–96.
- Nowak M, Madej JA, Dziegiel P: Correlation between MCM-3 protein expression and grade of malignancy in mammary adenocarcinomas and soft tissue fibrosarcomas in dogs. In Vivo 2009, 23(1):49–53.
- Liu X, Liu Y, Wang Q, Song S, Feng L, Shi C: The Alterations and Potential Roles of MCMs in Breast Cancer. J Oncol 2021, 2021:7928937.
- Cheng L, Tan Z, Huang Z, Pan Y, Zhang W, Wang J: Expression Profile and Prognostic Values of Mini-Chromosome Maintenance Families (MCMs) in Breast Cancer. Med Sci Monit 2020, 26:e923673.
- Murakami Y, Tateyama S, Rungsipipat A, Uchida K, Yamaguchi R: Immunohistochemical analysis of cyclin A, cyclin D1 and P53 in mammary tumors, squamous cell carcinomas and basal cell tumors of dogs and cats. J Vet Med Sci 2000, 62(7):743–750.
- Kaszak I, Witkowska-Piłaszewicz O, Domrazek K, Jurka P: The Novel Diagnostic Techniques and Biomarkers of Canine Mammary Tumors. Vet Sci 2022, 9(10).
- Muscatello LV, Gobbo F, Di Oto E, Sarli G, De Maria R, De Leo A, Tallini G, Brunetti B: HER2 Overexpression and Cytogenetical Patterns in Canine Mammary Carcinomas. Vet Sci 2022, 9(11).
- Araújo MR, Campos LC, Damasceno KA, Gamba CO, Ferreira E, Cassali GD: HER-2, EGFR, Cox-2 and Ki67 expression in lymph node metastasis of canine mammary carcinomas: Association with clinical-pathological parameters and overall survival. Res Vet Sci 2016, 106:121–130.
- Aydogan A, Ozmen O, Haligur M, Sipahi C, Ileri D, Haligur A: Immunohistochemical evaluation of bcl-2, ER-alpha, caspase – 3, – 8, – 9, PCNA and Ki-67 expressions in canine mammary carcinomas. Biotech Histochem 2018, 93(4):286–292.
- Kumaraguruparan R, Prathiba D, Nagini S: Of humans and canines: Immunohistochemical analysis of PCNA, Bcl-2, p53, cytokeratin and ER in mammary tumours. Res Vet Sci 2006, 81(2):218–224.
- Sankari SL, Masthan KM, Babu NA, Bhattacharjee T, Elumalai M: Apoptosis in cancer— an update. Asian Pac J Cancer Prev 2012, 13(10):4873–4878.
- Yang ZJ, Chee CE, Huang S, Sinicrope FA: The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 2011, 10(9):1533–1541.
- Chude CI, Amaravadi RK: Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors. Int J Mol Sci 2017, 18(6).
- Lane DP: Cancer. p53, guardian of the genome. Nature 1992, 358(6381):15–16.
- Artandi SE, Attardi LD: Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. Biochem Biophys Res Commun 2005, 331(3):881–890.
- Krock BL, Skuli N, Simon MC: Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2011, 2(12):1117–1133.
- Mees G, Vangestel C, Dierckx R, Loomans S, Van Damme N, Peremans K, De Rooster H, Van Goethem B, Pauwels P, Ducatelle R et al: Metabolic correlates of tumour hypoxia in malignant canine mammary carcinoma. Res Vet Sci 2011, 91(3):e125–128.
- Kim TH, Lee JH, An JH, Ko BG, Kim KB, Youn HY: Hypoxia Increases the Proliferative and Metastatic Ability of Canine Mammary Tumor Cells via Up-regulation of TSG-6. Anticancer Res 2022, 42(12):5803–5812.
- Shin JI, Lim HY, Kim HW, Seung BJ, Sur JH: Analysis of Hypoxia-Inducible Factor-1α Expression Relative to Other Key Factors in Malignant Canine Mammary Tumours. J Comp Pathol 2015, 153(2–3):101–110.
- Moschetta MG, Maschio LB, Jardim-Perassi BV, Gelaleti GB, Lopes JR, Leonel C, Gonçalves Ndo N, Ferreira LC, Martins GR, Borin TF et al: Prognostic value of vascular endothelial growth factor and hypoxia-inducible factor 1α in canine malignant mammary tumors. Oncol Rep 2015, 33(5):2345–2353.
- Abdelmegeed SM, Mohammed S: Canine mammary tumors as a model for human disease. Oncol Lett 2018, 15(6):8195–8205.
- Ribatti D, Tamma R, Annese T: Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. Translational Oncology 2020, 13(6):100773.
- Gray M, Meehan J, Martínez-Pérez C, Kay C, Turnbull AK, Morrison LR, Pang LY, Argyle D: Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer. Front Oncol 2020, 10:617.
- Raposo-Ferreira TMM, Brisson BK, Durham AC, Laufer-Amorim R, Kristiansen V, Puré E, Volk SW, Sorenmo K: Characteristics of the Epithelial-Mesenchymal Transition in Primary and Paired Metastatic Canine Mammary Carcinomas. Vet Pathol 2018, 55(5):622–633.
- Leonel C, Borin TF, de Carvalho Ferreira L, Moschetta MG, Bajgelman MC, Viloria-Petit AM, de Campos Zuccari DA: Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model. J Mammary Gland Biol Neoplasia 2017, 22(1):27–41.
- Xavier PLP, Cordeiro YG, Rochetti AL, Sangalli JR, Zuccari D, Silveira JC, Bressan FF, Fukumasu H: ZEB1 and ZEB2 transcription factors are potential therapeutic targets of canine mammary cancer cells. Vet Comp Oncol 2018, 16(4):596–605.
- Sammarco A, Gomiero C, Beffagna G, Cavicchioli L, Ferro S, Michieletto S, Orvieto E, Patruno M, Zappulli V: Epithelial-to-Mesenchymal Transition and Phenotypic Marker Evaluation in Human, Canine, and Feline Mammary Gland Tumors. Animals (Basel) 2023, 13(5).
- Braicu C, Chiorean R, Irimie A, Chira S, Tomuleasa C, Neagoe E, Paradiso A, Achimas-Cadariu P, Lazar V, Berindan-Neagoe I: Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy. Expert Rev Mol Med 2016, 18:e18.
- Sakalauskaitė S, Šaltenienė V, Nikitina D, Ugenskienė R, Riškevičienė V, Karvelienė B, Juodžiukynienė N: VEGF-B, VEGF-A, FLT-1, KDR, ERBB2, EGFR, GRB2, RAC1, CDH1 and HYAL-1 Genes Expression Analysis in Canine Mammary Gland Tumors and the Association with Tumor ClinicoPathological Parameters and Dog Breed Assessment. Vet Sci 2021, 8(10).
- Prado MCM, Macedo SAL, Guiraldelli GG, de Faria Lainetti P, Leis-Filho AF, Kobayashi PE, Laufer-Amorim R, Fonseca-Alves CE: Investigation of the Prognostic Significance of Vasculogenic Mimicry and Its Inhibition by Sorafenib in Canine Mammary Gland Tumors. Front Oncol 2019, 9:1445.
- Carvalho MI, Guimarães MJ, Pires I, Prada J, Silva-Carvalho R, Lopes C, Queiroga FL: EGFR and microvessel density in canine malignant mammary tumours. Res Vet Sci 2013, 95(3):1094–1099.
- Queiroga FL, Pires I, Parente M, Gregório H, Lopes CS: COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary cancer. Vet J 2011, 189(1):77–82.
- Guimarães MJ, Carvalho MI, Pires I, Prada J, Gil AG, Lopes C, Queiroga FL: Concurrent expression of cyclo-oxygenase-2 and epidermal growth factor receptor in canine malignant mammary tumours. J Comp Pathol 2014, 150(1):27–34.
- Xu E, Hu M, Liu Y: Aspirin inhibits proliferation and metastasis of canine mammary gland tumor cells through Wnt signaling axis. Transl Cancer Res 2021, 10(2):589–601.
- Rajakylä K, Krishnan R, Tojkander S: Analysis of Contractility and Invasion Potential of Two Canine Mammary Tumor Cell Lines. Front Vet Sci 2017, 4:149.
- de Oliveira JT, Ribeiro C, Barros R, Gomes C, de Matos AJ, Reis CA, Rutteman GR, Gärtner F: Hypoxia Up-Regulates Galectin-3 in Mammary Tumor Progression and Metastasis. PLoS One 2015, 10(7):e0134458.
- Klopfleisch R, Lenze D, Hummel M, Gruber AD: Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles. BMC Cancer 2010, 10:618.
- Ren X, Fan Y, Shi D, Liu Y: Expression and significance of IL-6 and IL-8 in canine mammary gland tumors. Scientific Reports 2023, 13(1):1302.
- Jang H, Choi J, Park JK, Won G, Seol JW: Fucoxanthin Exerts Anti-Tumor Activity on Canine Mammary Tumor Cells via Tumor Cell Apoptosis Induction and Angiogenesis Inhibition. Animals (Basel) 2021, 11(6).
- Liu Y, Li W, Guo M, Li C, Qiu C: Protective Role of Selenium Compounds on the Proliferation, Apoptosis, and Angiogenesis of a Canine Breast Cancer Cell Line. Biol Trace Elem Res 2016, 169(1):86–93.
- Lavalle GE, Bertagnolli AC, Tavares WL, Cassali GD: Cox-2 expression in canine mammary carcinomas: correlation with angiogenesis and overall survival. Vet Pathol 2009, 46(6):1275–1280.
- Gama A, Gärtner F, Alves A, Schmitt F: Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues. Res Vet Sci 2009, 87(3):432–437.
- Klopfleisch R, Lenze D, Hummel M, Gruber AD: The metastatic cascade is reflected in the transcriptome of metastatic canine mammary carcinomas. Vet J 2011, 190(2):236–243.
- Qiu CW, Lin DG, Wang JQ, Li CY, Deng GZ: Expression and significance of PTEN and VEGF in canine mammary gland tumours. Vet Res Commun 2008, 32(6):463–472.
- Rezaee M, Movassaghi AR, Maleki M: Immunohistochemical expression of transforming growth factor Beta-1 in canine mammary carcinomas: its relationships with histologic grading, survival rate, and recurrence. Comparative Clinical Pathology 2017, 26(3):519–524.
- Carvalho MI, Pires I, Prada J, Pinto C, Gregório H, Cogliati B, Queiroga FL: Assessing the Interleukin 35 Immunoexpression in Malignant Canine Mammary Tumors: Association With Clinicopathological Parameters and Prognosis. Anticancer Res 2019, 39(4):2077–2083.
- Rybicka A, Król M: Identification and characterization of cancer stem cells in canine mammary tumors. Acta Vet Scand 2016, 58(1):86.
- Michishita M: Understanding of tumourigenesis in canine mammary tumours based on cancer stem cell research. The Veterinary Journal 2020, 265:105560.
- Michishita M, Ochiai K, Nakahira R, Azakami D, Machida Y, Nagashima T, Nakagawa T, Ishiwata T: mTOR pathway as a potential therapeutic target for cancer stem cells in canine mammary carcinoma. Front Oncol 2023, 13:1100602.
- Zamani-Ahmadmahmudi M: Embryonic stem cell gene expression signatures in the canine mammary tumor: a bioinformatics approach. Apmis 2016, 124(8):659–668.
- Barreno L, Cáceres S, Alonso-Diez Á, Vicente-Montaña A, García ML, Clemente M, Illera JC, Peña L: Vasculogenic mimicry-associated ultrastructural findings in human and canine inflammatory breast cancer cell lines. BMC Cancer 2019, 19(1):750.
- Barbieri F, Thellung S, Ratto A, Carra E, Marini V, Fucile C, Bajetto A, Pattarozzi A, Würth R, Gatti M et al: In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors. BMC Cancer 2015, 15:228.
- Pang LY, Cervantes-Arias A, Else RW, Argyle DJ: Canine Mammary Cancer Stem Cells are Radio – and Chemo – Resistant and Exhibit an Epithelial-Mesenchymal Transition Phenotype. Cancers (Basel) 2011, 3(2):1744–1762.
- Du H, Zhou B, Zhang H, Jin Y, Zhang D, Lin D: Salinomycin inhibits canine mammary carcinoma in vitro by targeting cancer stem cells. Oncol Lett 2017, 14(1):427–432.
- Bulkowska M, Rybicka A, Senses KM, Ulewicz K, Witt K, Szymanska J, Taciak B, Klopfleisch R, Hellmén E, Dolka I et al: MicroRNA expression patterns in canine mammary cancer show significant differences between metastatic and non-metastatic tumours. BMC Cancer 2017, 17(1):728.
- Lu B, Wu J, Chen H, Li S, Jia K: LncRNA Expression Profiles in Canine Mammary Tumors Identify lnc34977 as a Promoter of Proliferation, Migration and Invasion of Canine Mammary Tumor Cells. Vet Sci 2022, 9(2).
- Kim EP, Jang G, Kim JW, Kim SW, Chung H, Yang YJ, Kim WH, Kim GA: MicroRNA and Messenger RNA Expression Profiles in Canine Mammary Gland Tumor. Int J Mol Sci 2023, 24(3).
- Agarwal P, Crepps MP, Stahr NA, Kretzschmar WP, Harris HC, Prasad N, Levy SE, Smith BF: Identification of canine circulating miRNAs as tumor biospecific markers using Next-Generation Sequencing and Q-RT-PCR. Biochem Biophys Rep 2021, 28:101106.
- Fish EJ, Martinez-Romero EG, DeInnocentes P, Koehler JW, Prasad N, Smith AN, Bird RC: Circulating microRNA as biomarkers of canine mammary carcinoma in dogs. J Vet Intern Med 2020, 34(3):1282–1290.
- Ramadan ES, Salem NY, Emam IA, AbdElkader NA, Farghali HAM, Khattab MS: MicroRNA-21 expression, serum tumor markers, and immunohistochemistry in canine mammary tumors. Veterinary Research Communications 2021, 46:377 – 388.
- Ren X, Fan Y, Shi D, Xu E, Liu Y: MicroRNA-124 inhibits canine mammary carcinoma cell proliferation, migration and invasion by targeting CDH2. Res Vet Sci 2022, 146:5–14.
- Wucher V, Legeai F, Hédan B, Rizk G, Lagoutte L, Leeb T, Jagannathan V, Cadieu E, David A, Lohi H et al: FEELnc: a tool for long non-coding RNA annotation and its application to the dog transcriptome. Nucleic Acids Res 2017, 45(8):e57.
- Le Béguec C, Wucher V, Lagoutte L, Cadieu E, Botherel N, Hédan B, De Brito C, Guillory A-S, André C, Derrien T et al: Characterisation and functional predictions of canine long non-coding RNAs. Scientific Reports 2018, 8(1):13444.
- Xu E, Hu M, Ge R, Tong D, Fan Y, Ren X, Liu Y: LncRNA-42060 Regulates Tamoxifen Sensitivity and Tumor Development via Regulating the miR-204-5p/SOX4 Axis in Canine Mammary Gland Tumor Cells. Front Vet Sci 2021, 8:654694.
- von Deetzen MC, Schmeck BT, Gruber AD, Klopfleisch R: Malignancy Associated MicroRNA Expression Changes in Canine Mammary Cancer of Different Malignancies. ISRN Vet Sci 2014, 2014:148597.